Infirst Healthcare Limited

Wilson Caparros Wanderley

Robin Mark Bannister

John Brew

Richard R Reiley, Iii

Gregory Alan Stoloff

Suzanne Jane Dilly

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions and use in chronic inflammation

The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid in an amount of less than about 55%, one or more pharmaceutically-acceptable hard fats in an amount of at least 25% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of 1% to 50% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions and use in severe pain

The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions comprising cannabidiols

The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of less than 45% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions and use in cardiovascular disease

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Growing community of inventors

Buckinghamshire, United Kingdom

Wilson Caparros Wanderley